Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: Improved immunogenicity using a Bvg-regulated promoter to express FrgC

Vaccine

Volumn 22, Issue 31-32, 2004, Pages 4300-4305

  Stevenson, Andrew ^a   Roberts, Mark ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Attenuated Bordetella bronchiseptica; Mucosal tetanus vaccines

Indexed keywords

BACTERIAL VACCINE; DRUG CARRIER; INTERLEUKIN 2 RECEPTOR; PROTEIN ANTIBODY; TETANUS TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENETIC CODE; GENETIC REGULATION; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROVOCATION TEST; SURVIVAL; TETANUS;

ADHESINS, BACTERIAL; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA BRONCHISEPTICA; DNA PRIMERS; DNA, BACTERIAL; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VECTORS; HEMAGGLUTININS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PLASMIDS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETANUS; TETANUS TOXIN; TETANUS TOXOID; TRANSFORMATION, GENETIC; VIRULENCE FACTORS, BORDETELLA;

EID: 4944236208     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.04.020     Document Type: Article

References (32)

1. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 10(2):1992;75-88
2. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A.M. Mucosal immunity: implications for vaccine development. Immunobiology. 184(2-3):1992;157-179
3. Roberts M, Chatfield SN, Dougan G. Salmonella as carriers of heterologous antigens. In: Novel delivery systems for oral vaccines. CRC Press; 1994. p. 27-58.
4. Chatfield S.N., Charles I.G., Makoff A.J., et al. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (N.Y.). 10(8):1992;888-892
5. Chatfield S.N., Fairweather N., Charles I., et al. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine. 10(1):1992;53-60
6. Levine M.M., Galen J., Barry E., et al. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J. Biotechnol. 44(1/3):1996;193-196
7. Roberts M., Li J., Bacon A., Chatfield S. Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters. Infect. Immun. 66(7):1998;3080- 3087. [published erratum appears in Infect Immun 1999;67(January (1)):468]
8. Stevenson A., Roberts M. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol. Med. Microbiol. 37(2-3):2003;121-128
9. Mielcarek N., Alonso S., Locht C. Nasal vaccination using live bacterial vectors. Adv. Drug Deliv. Rev. 51(1-3):2001;55-69
10. Goodnow R.A. Biology of Bordetella bronchiseptica. Microbiol. Rev. 44:1980;722-738
11. Woolfrey B.F., Moody J.A. Human infections associated with Bordetella bronchiseptica. Clin. Microbiol. Rev. 4(3):1991;243-255
12. Roberts M, Parton R. Bordetella pertussis. In: Molecular medical microbiology, vol. 75. 1st ed. Academic Press; 2001. p. 1565-618.
13. Cotter P.A., Miller J.F. Genetic analysis of the Bordetella infectious cycle. Immunopharmacology. 48(3):2000;253-255
14. Novotny P., Kobisch M., Cownley K., Chubb A.P., Montaraz J.A. Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen-free piglets with bacterial cell surface antigens in enzyme-linked immunosorbent assay. Infect. Immun. 50(1):1985;190-198
15. Ellis J.A., Haines D.M., West K.H., et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. J. Am. Vet. Med. Assoc. 218(3):2001;367-375
16. Elias B., Gergely P., Boros G. Epizootiological studies on porcine atrophic rhinitis. XV. Results of local immunization with a live Bordetella bronchiseptica strain in a large-scale pig herd affected by atrophic rhinitis. Acta Vet. Hung. 36(3-4):1988;195-204
17. Matherne C.M., Steffen E.K., Wagner J.E. Efficacy of commercial vaccines for protecting guinea pigs against Bordetella bronchiseptica pneumonia. Lab. Anim. Sci. 37(2):1987;191-194
18. Strugnell R., Dougan G., Chatfield S., et al. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect. Immun. 60(10):1992;3994-4002
19. Smith I.M., Baskerville A.J., Brothwell E., Oliphant J. Immunogenicity of killed Bordetella bronchiseptica vaccines in the mouse. Res. Vet. Sci. 32(2):1982;248-252
20. Roberts M., Cropley I., Chatfield S., Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine. 11(8):1993;866-872
21. Bey R.F., Shade F.J., Goodnow R.A., Johnson R.C. Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am. J. Vet. Res. 42(7):1981;1130-1132
22. Roberts M., Maskell D., Novotny P., Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect. Immun. 58(3):1990;732-739
23. Stevenson A, Roberts M. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine 2002;20(May (17-18)):2325-35.
24. Forde C.B., Shi X., Li J., Roberts M. Bordetella bronchiseptica-mediated cytotoxicity to macrophages is dependent on bvg-regulated factors, including pertactin. Infect. Immun. 67(11):1999;5972-5980
25. Kovach M.E., Elzer P.H., Hill D.S., et al. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene. 166(1):1995;175-176
26. Sambrook J, Fritsch EF, Mattick JS. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press; 1989.
27. Rajeev S., Nair R.V., Kania S.A., Bemis D.A. Expression of a truncated Pasteurella multocida toxin antigen in Bordetella bronchiseptica. Vet. Microbiol. 94(4):2003;313-323
28. Reveneau N., Alonso S., Jacob-Dubuisson F., Mercenier A., Locht C. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine. 20:2001;926-933
29. Coppens I., Alonso S., Antoine R., et al. Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis. Infect. Immun. 69(9):2001;5440-5446
30. Mielcarek N., Cornette J., Schacht A.M., et al. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65(2):1997;544-550
31. Mielcarek N., Riveau G., Remoue F., Antoine R., Capron A., Locht C. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16(5):1998;454-457
32. Renauld-Mongenie G., Mielcarek N., Cornette J., et al. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc. Natl. Acad. Sci. U.S.A. 93(15):1996;7944-7949